New trial combines lifestyle changes and Weight-Loss drug to boost mental health

NCT ID NCT07586150

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a personalized program of exercise, diet, sleep support, social activities, and a weight-loss drug (semaglutide) can improve mental functioning in 140 adults with depression, bipolar disorder, or schizophrenia. Participants are randomly assigned to the personalized program or a standard education group. The main goal is to see if mental health scores improve after 3 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Semaglutide (a once-weekly injection for weight loss and metabolic health), plus personalized exercise, anti-inflammatory diet, sleep intervention, social prescribing, and optional brain stimulation

What this could lead to

If it works, this could point toward a practical, personalized treatment plan that improves mental and physical health for people with severe mental illness.

What could go wrong

This is an early-stage trial with only 140 participants, so results may not apply to everyone. The lifestyle changes require significant effort, and semaglutide can cause side effects like nausea or vomiting.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bipolar disorder Depression major depressive disorder psychiatric disorder schizophrenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Central Institute of Mental Health

    Mannheim, 68159, Germany

  • Department of Psychiatry and Psychotherapy, LMU Klinikum

    München, 80336, Germany

  • Medical University of Vienna

    Vienna, 1090, Austria

  • University Medical Center Groningen

    Groningen, 9713 GZ, Netherlands

  • University Medical Center Utrecht

    Utrecht, 3584 CX, Netherlands